Immuneering Stock (NASDAQ:IMRX)
Previous Close
$1.87
52W Range
$1.00 - $8.89
50D Avg
$2.02
200D Avg
$2.57
Market Cap
$55.16M
Avg Vol (3M)
$5.68M
Beta
-0.45
Div Yield
-
IMRX Company Profile
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Performance
Peer Comparison
Ticker | Company |
---|---|
PMVP | PMV Pharmaceuticals, Inc. |
GOSS | Gossamer Bio, Inc. |
CGEM | Cullinan Oncology, Inc. |
IVA | Inventiva S.A. |
CNTA | Centessa Pharmaceuticals plc |
IKNA | Ikena Oncology, Inc. |
LRMR | Larimar Therapeutics, Inc. |
REPL | Replimune Group, Inc. |
KRON | Kronos Bio, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
NAMS | NewAmsterdam Pharma Company N.V. |
LYRA | Lyra Therapeutics, Inc. |
CELC | Celcuity Inc. |
NVCT | Nuvectis Pharma, Inc. |
ELVN | Enliven Therapeutics, Inc. |
CMPX | Compass Therapeutics, Inc. |